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included patients at high risk of recurrent AF. This study is
consistent with the results of the Framingham Offspring
Study (no association between interleukin-6 or CRP and new-
onset AF). Taken together, these studies suggest that
inflammation may contribute to the generation of AF in some
patients, but is unlikely to be a major determinant of recur-
rences in the general population of AF patients.   
Summary written by: Fred Morady, MD
Chest-Compression-Only Versus Standard
Cardiopulmonary Resuscitation: A Meta-Analysis
Hupfl M, Selig HF, Nagele P.
Lancet 2010;376:1552–1557.
Study Question: Does chest-compression-only resuscitation
(CCOR) improve outcomes compared to conventional car-
diopulmonary resuscitation (CCPR)? 
Methods: This was a meta-analysis of three randomized clinical
trials (RCTs) and seven observational cohort studies in which
bystanders were instructed to perform either CCOR or CCPR
after reporting an out-of-hospital cardiac arrest (OHCA). The
primary outcome was survival to hospital discharge.
Results: In the RCTs, the overall sample sizes were 1,500 in
the CCOR group and 1,531 in the CCPR group. Survival to
hospital discharge was significantly higher in the CCOR
(14%) than the CCPR (12%) group. In the nonrandomized
cohort studies, the overall sample sizes were 2,731 in the
CCOR group and 11,152 in the CCPR group. Survival to
hospital discharge was 8% in both groups.
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Arrhythmias
Predicting Atrial Fibrillation Recurrence With
Circulating Inflammatory Markers in Patients in
Sinus Rhythm at High Risk for Atrial Fibrillation:
Data From the GISSI Atrial Fibrillation Trial
Masson S, Aleksova A, Favero C, et al.
Heart 2010;96:1909–1914.
Study Question: Are markers of inflammation predictive of
recurrent atrial fibrillation (AF)?   
Methods: Interleukin-6, high-sensitivity C-reactive protein
(hs-CRP), and pentraxin-3 plasma concentrations were
measured at baseline and 6 and 12 months of follow-up in
382 patients (mean age 68 years) with a history of AF.
Episodes of AF during follow-up were detected by symp-
toms or weekly transtelephonic monitor recordings.
Results: AF recurred at least once during follow-up in 53% of
patients. Baseline median concentrations of the three inflam-
matory markers did not differ significantly between patients
with and without recurrent AF during follow-up. None of the
three inflammatory markers by themselves or in combination
were significant predictors of recurrent AF.
Conclusions: Inflammatory markers are not predictive of
recurrent AF in patients with a history of AF.
Perspective: Several small studies have demonstrated that
inflammatory markers such as hs-CRP are predictive of recur-
rent AF after cardioversion or radiofrequency catheter ablation
of AF. The present study had a larger sample size and
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Cardiovascular Surgery
Aspirin Plus Clopidogrel Versus Aspirin Alone After
Coronary Artery Bypass Grafting: The Clopidogrel
After Surgery for Coronary Artery Disease 
(CASCADE) Trial 
Kulik A, Le May MR, Voisine P, et al.
Circulation 2010;122:2680–2687.
Study Question: What is the effect of the addition of clopido-
grel to aspirin in inhibiting saphenous vein graft (SVG)
disease after coronary artery bypass grafting (CABG)?     
Methods: In CASCADE, a double-blind phase II trial, 113
patients undergoing CABG with SVGs were randomized to
receive aspirin 162 mg plus clopidogrel 75 mg daily or
aspirin 162 mg plus placebo daily for 1 year. The primary
outcome was SVG intimal hyperplasia, as determined by
intravascular ultrasound at 1 year. Secondary outcomes were
graft patency, major adverse cardiovascular events, and major
bleeding. One-year intravascular ultrasound and coronary
angiography were performed in 92 patients (81.4%).
Results: SVG intimal area did not differ significantly between
groups (4.1 ± 2.0 vs. 4.5 ± 2.1 mm2, aspirin-clopidogrel vs.
aspirin-placebo, all respectively; p = 0.44). Overall 1-year graft
patency was 95.2% versus 95.5%, and SVG patency was 94.3%
versus 93.2% (p = 0.69). Freedom from major adverse cardio-
vascular events at 1 year was 92.9 ± 3.4% in the
aspirin-clopidogrel and 91.1 ± 3.8% in the aspirin-placebo
group (p = 0.76). The incidence of major bleeding at 1 year
was similar for the two groups (1.8% vs. 0%, p = 0.50).
Conclusions: Compared with aspirin monotherapy, the com-
bination of aspirin plus clopidogrel did not significantly
reduce the process of SVG intimal hyperplasia after CABG.
Perspective: This study suggests that the addition of clopido-
grel to aspirin may not lead to a significant reduction in
intimal hyperplasia at 1 year. Although CASCADE was not
powered for angiographic or clinical outcomes, there were
no significant differences in SVG patency or cardiovascular
events between the groups. A larger trial with clopidogrel or
newer antiplatelet agents with more consistent inhibition of
the P2Y12 receptor may provide additional insight into the
role of these agents for the inhibition of SVG disease.  
Summary written by: Debabrata Mukherjee, MD
Congenital Heart Disease
Mortality Resulting From Congenital Heart Disease
Among Children and Adults in the United States,
1999 to 2006
522 Eagle, Cannon
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Conclusions: Compared to CCPR, CCOR by bystanders
improves survival in victims of OHCA.
Perspective: This study demonstrates the value of a meta-
analysis when a therapeutic effect is modest. Although
survival to hospital discharge tended to be higher with
CCOR than CCPR in the three RCTs, the difference was
not significant in any of the studies. By meta-analysis of the
three studies, a significant improvement in outcomes with
CCOR was demonstrated. Although modest, an absolute
increase in survival of 2% with bystander CCOR for OHCA
translates to a few thousand lives saved per year.   
Summary written by: Fred Morady, MD
Metoprolol Versus Amiodarone in the Prevention
of Atrial Fibrillation After Cardiac Surgery: A
Randomized Trial
Halonen J, Loponen P, Jarvinen O, et al.
Ann Intern Med 2010;153:703–709.
Study Question: Is metoprolol as effective as amiodarone for
preventing post-cardiac surgery atrial fibrillation (AF)?   
Methods: In this prospective study, 316 patients (mean age 64
years) with no history of AF underwent on-pump coronary
artery bypass grafting and/or aortic valve surgery. The
patients were randomly assigned to receive a 48-hour infu-
sion of metoprolol (n = 159), 1-3 mg/h depending on heart
rate, or amiodarone (n = 157), 15 mg/kg/d with maximum of
1000 mg/24 h, starting 15-20 hours after the operation.
Continuous electrocardiographic monitoring was performed
and the primary endpoint was the first episode of AF lasting
>5 minutes.
Results: A similar percentage of patients experienced AF in the
metoprolol (23.9%) and amiodarone (24.8%) groups.
However, because of large confidence intervals, a significant
difference between the two groups could not be ruled out.
The mean duration of hospitalization was 5.5 days and did
not differ significantly between groups.
Conclusions: Prophylactic therapy with metoprolol or amio-
darone results in a similar risk of AF after cardiac surgery,
but this study was underpowered to exclude a significant
difference in efficacy.
Perspective: This study strongly suggests that a significant
difference in efficacy would be minor in magnitude. This is
consistent with published meta-analyses in which metopro-
lol and amiodarone reduced the risk of postoperative AF by
61% and 62%, respectively. The data validate the current
recommendation of the European Association for
Cardiothoracic Surgery to reserve amiodarone for patients in
whom beta-blocker therapy fails or cannot be used.  
Summary written by: Fred Morady, MD
(ALA) on the rate of cardiovascular events (CVEs) in per-
sons who have had a myocardial infarction (MI)? 
Methods: Alpha Omega Alpha was a multicenter, double-blind,
placebo-controlled trial conducted over 4 years, that randomly
assigned 4,837 patients, ages 60-80 years, who have had an
MI and were receiving antihypertensive (89.7%), antithrom-
botic (97.5%), and lipid-modifying (86.0%) therapy. Subjects
were randomized to one of four trial margarines supplemented
with the following: a combination of EPA+DHA (400 mg of
EPA+DHA), ALA (2 g of ALA), EPA+DHA and ALA, or
a placebo margarine. The primary endpoint was the rate of
major CVEs, which comprised fatal and nonfatal CVEs and
cardiac interventions. Data were analyzed according to inten-
tion-to-treat, with Cox proportional-hazards models.
Results: Mean age was 69 years and 78% were men, 16.9%
smokers, 24% obese, and 21% diabetics. The median period
between MI and entry was 3.7 years. Patients consumed, on
average, 18.8 g of margarine per day, which resulted in addi-
tional intakes of 226 mg of EPA+150 mg of DHA, 1.9 g of
ALA, or both, in the active-treatment groups. With a median
follow-up of 40.8 months and 15,531 patient-years, a major
CVE occurred in 671 patients (13.9%). Neither EPA+DHA
nor ALA reduced the primary endpoint. In the prespecified
subgroup of women, ALA, as compared with placebo and
EPA+DHA alone, was associated with a reduction in the rate
of major CVEs that approached significance (hazard ratio,
0.73; 95% CI, 0.51-1.03; p = 0.07). Adverse events did not
differ significantly among groups.
Conclusions: Low-dose supplementation with EPA+DHA or
ALA did not significantly reduce the rate of major CVEs
among patients who have had an MI and who were receiv-
ing state-of-the-art antihypertensive, antithrombotic, and
lipid-modifying therapy.
Perspective: Observational studies and randomized trials sug-
gest a protective effect of marine sources of omega-3 fatty
acids in persons with cardiovascular disease. This trial was
well designed and appropriately powered based upon available
evidence. Why was it negative? The most likely reason is the
relative weak effect of EPA+DHA in patients on evidence-
based treatments. The effect of high-dose EPA+DHA
(1000-4000 mg) needs to be assessed prior to concluding a
lack of benefit.  
Summary written by: Melvyn Rubenfire, MD
Oral Rivaroxaban for Symptomatic Venous
Thromboembolism 
The EINSTEIN Investigators.
N Engl J Med 2010;363:2499–2510. 
Study Question: What is the efficacy and safety of rivaroxaban
compared with standard therapy consisting of enoxaparin and
a vitamin K antagonist in patients with acute, symptomatic
Gilboa SM, Salemi JL, Nembhard WN, Fixler DE, Correa A.
Circulation 2010;122:2254–2263.
Study Question: What are the temporal trends of mortality
resulting from congenital heart disease from 1999 to 2006?  
Methods: Death certificate data filed in the United States
from 1999 to 2006 were used to calculate annual congenital
heart disease mortality by age at death, race-ethnicity, and
sex. For individuals ≥1 year of age, population counts from
the US Census were used, whereas live birth rates were used
to calculate infant mortality. 
Results: Over the study period, 41,494 congenital heart dis-
ease-related deaths and 27,960 deaths resulting from
congenital heart disease (age standardized mortality rates, 1.78
and 1.20 per 100,000, respectively) occurred. There was an
overall decline in congenital heart disease mortality of 24.1%
over the study period. While age-related mortality declined
among all race-ethnicities studied, overall and infant mortality
was higher among non-Hispanic blacks compared with non-
Hispanic whites. Infant mortality accounted for 48% of all
mortality resulting from congenital heart disease.  
Conclusions: Mortality from congenital heart disease continues
to decline in children and adults, with persistent differences
between race-ethnicities. Although mortality in infancy con-
tinues, late mortality is significant, emphasizing the
importance of infrastructure for the care of adults with con-
genital heart disease.
Perspective: This study is among a series of papers published
over the last several months investigating changing patterns of
mortality in congenital heart disease. In the current paper,
Gilboa, et al. reported steady improvement in survival in all
age groups over a relatively short time course (1999-2006).
This study showed a strikingly higher proportion of deaths
occurring in infancy (48%) in the most recent surgical era than
the Canadian study (<5%); the reasons are unclear and deserve
further study. All studies agree that more infants and children
with congenital heart disease are surviving to adulthood, and
that the medical community will need to prepare for the care
of more adults with more complex congenital heart disease.  
Summary written by: Timothy B. Cotts, MD
General Cardiology
n–3 Fatty Acids and Cardiovascular Events After
Myocardial Infarction 
Kromhout D, Giltay EJ, Geleijnse JM, et al., on behalf of the Alpha
Omega Trial Group.
N Engl J Med 2010;363:2015–2026.
Study Question: What is the effect of the marine n−3 fatty
acids eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA), and of the plant-derived alpha-linolenic acid
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deep-vein thrombosis (DVT)? 
Methods: The EINSTEIN–DVT investigators conducted an
open-label, randomized, event-driven, noninferiority study
that compared oral rivaroxaban alone (15 mg twice daily for
3 weeks, followed by 20 mg once daily) with subcutaneous
enoxaparin, followed by a vitamin K antagonist (either war-
farin or acenocoumarol) for 3, 6, or 12 months in patients
with acute, symptomatic DVT. In parallel, they carried out
a double-blind, randomized, event-driven superiority study
(EINSTEIN–Extension) that compared rivaroxaban alone
(20 mg once daily) with placebo for an additional 6 or 12
months in patients who had completed 6 to 12 months of
treatment for venous thromboembolism. The primary effi-
cacy outcome for both studies was recurrent venous
thromboembolism. The principal safety outcome was major
bleeding or clinically relevant nonmajor bleeding in the ini-
tial-treatment study and major bleeding in the
continued-treatment study.
Results: The study of rivaroxaban for acute DVT included
3,449 patients: 1,731 given rivaroxaban and 1,718 given
enoxaparin plus a vitamin K antagonist. Rivaroxaban had
noninferior efficacy with respect to the primary outcome (36
events [2.1%] vs. 51 events with enoxaparin–vitamin K
antagonist [3.0%]; p < 0.001). The principal safety outcome
occurred in 8.1% of the patients in each group. In the con-
tinued-treatment study, which included 602 patients in the
rivaroxaban group and 594 in the placebo group, rivaroxa-
ban had superior efficacy (8 events [1.3%] vs. 42 with
placebo [7.1%]; p < 0.001). Four patients in the rivaroxaban
group had nonfatal major bleeding (0.7%) versus none for
placebo (p = 0.11). 
Conclusions: Rivaroxaban offers a simple, single-drug
approach to the short-term and continued treatment of
venous thrombosis.
Perspective: This study suggests that rivaroxaban alone is as
effective as standard therapy, with similar safety, for the treat-
ment of acute DVT, and that when treatment is continued,
rivaroxaban is very effective in preventing recurrences, and has
an acceptable risk of bleeding. Furthermore, a prespecified
indicator of net clinical benefit (symptomatic recurrent venous
thromboembolism plus major bleeding) favored rivaroxaban.  
Summary written by: Debabrata Mukherjee, MD
Association of Troponin T Detected With a Highly
Sensitive Assay and Cardiac Structure and Mortality
Risk in the General Population 
de Lemos JA, Drazner MH, Omland T, et al.
JAMA 2010;304:2503–2512.
Study Question: What are the prevalence and determinants of
detectable cardiac troponin T (cTnT) in the population, and
are cTnT levels associated with pathological cardiac pheno-
types and subsequent mortality? 
Methods: cTnT levels were measured using both the standard
and the highly sensitive assays in 3,546 individuals ages 30-
65 years enrolled between 2000 and 2002 in the Dallas
Heart Study, a multiethnic, population-based cohort study.
Mortality follow-up was complete through 2007.
Participants were placed into five categories based on cTnT
levels. Magnetic resonance imaging measurements of cardiac
structure and function and mortality through a median of
6.4 years of follow-up were performed.
Results: In Dallas County, the prevalence of detectable cTnT
(≥0.003 ng/ml) was 25.0% with the highly sensitive assay ver-
sus 0.7% with the standard assay. Prevalence was 37.1% in
men versus 12.9% in women and 14.0% in participants
younger than 40 years versus 57.6% in those 60 years and
older. Prevalence of left ventricular hypertrophy increased
from 7.5% in the lowest cTnT category (<0.003 ng/ml) to
48.1% in the highest (≥0.014 ng/ml) (p < 0.001); prevalence of
left ventricular systolic dysfunction and chronic kidney disease
also increased across categories (p < 0.001 for each). During
the 6.4 years, there were 151 total deaths, including 62 cardio-
vascular disease deaths. All-cause mortality increased from
1.9% to 28.4% across higher cTnT categories (p < 0.001).  
Conclusions: In this population-based cohort, cTnT detected
with a highly sensitive assay was associated with structural
heart disease and subsequent risk for all-cause mortality.
Perspective: The study suggests that circulating cTnT is
detectable in ~25% of adults ages 30-65 years in the general
population using a highly sensitive assay, and higher levels of
cTnT are associated with cardiac structural abnormalities
including left ventricular hypertrophy and left ventricular sys-
tolic dysfunction. Since this assay detects cTnT in a significant
proportion of the general population, it is possible that wide-
spread application may expose some patients presenting with
noncardiac chest pain to unnecessary risk and expense of inva-
sive cardiac procedures. A higher threshold to diagnose myo-
cardial infarction may need to be set when using these assays.  
Summary written by: Debabrata Mukherjee, MD
Heart Failure/Transplant
Telemonitoring in Patients With Heart Failure 
Chaudhry SI, Mattera JA, Curtis JP, et al.
N Engl J Med 2010;363:2301–2309. 
Study Question: Does telephone-based computerized monitor-
ing improve outcomes in subjects with heart failure (HF)? 
Methods: This was a multicenter randomized study of tele-
monitoring versus usual care in higher risk subjects with
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terminal BNP (NT-BNP) testing in patients presenting to the
emergency room (ER) with acute dyspnea impact outcomes?  
Methods: This was a meta-analysis examining published
(January 1996-July 2010) randomized controlled trials that
evaluated the use of BNP or NT-BNP testing in patients 
presenting with acute dyspnea to the ER. Cochrane
Collaboration methodological guidelines were used to assess
study quality for study inclusion. Outcomes included mortality
(mainly 30-day), admissions, and/or length of hospital stay.
Results: Five trials encompassing 2,513 patients were
included. Physicians in four of five of these trials were
blinded to BNP results in the control group. Trial designs
and patients enrolled were very heterogeneous. ER-based
BNP testing provided no impact on all-cause mortality (95%
confidence interval [CI], 0.65-1.4). Trends toward reduced
admissions were noted with BNP testing (CI, 0.67-1.01).
Lengths of stay were significantly reduced (95% CI, -2.3 to 
-0.14 days) with BNP testing. 
Conclusions: BNP testing in the ER led to reduced length of
stay, but had no impact on mortality and no significant
impact on admissions.
Perspective: The major, but not surprising, finding from this
study is heterogeneity. It does not appear that ER-based BNP
testing impacts mortality, but may impact admission rates.
The lack of mortality significance again likely relates to the
heterogeneity of the patients studied across studies (wide con-
fidence intervals). Also, power was limited (30-day mortality
was <3%). The authors hypothesize that BNP testing may
impact hospital stay lengths by allowing for faster implemen-
tation of appropriate therapies in those with dyspnea (i.e.,
diuretics in those with heart failure).  
Summary written by: Jennifer Ann Cowger, MD
Prevention/Vascular
Maintaining a High Physical Activity Level Over 20
Years and Weight Gain
Hankinson AL, Daviglus ML, Bourchard C, et al.
JAMA 2010;304:2603–2610.
Study Question: What is the relationship between habitual
activity levels and changes in body mass index (BMI) and
waist circumference over 20 years? 
Methods: The Coronary Artery Risk Development in Young
Adults (CARDIA) study is a prospective longitudinal study
with 20 years of follow-up (1985-1986 to 2005-2006).
Habitual activity was defined as maintaining high, moder-
ate, and low activity levels based on sex-specific tertiles of
activity scores at baseline. Participants comprised a popula-
tion-based multicenter cohort of 3,554 men and women
systolic and/or diastolic HF. All subjects had been hospital-
ized within 30 days and individuals unable to participate in
telemonitoring were excluded. Subjects randomized to tele-
monitoring were instructed to call a toll-free commercial
telemonitoring system daily to answer HF-related questions.
Telemonitoring information was reviewed by site coordina-
tors daily with “triggered variances” in subject answers sent to
clinicians for review. Patient and clinician adherence with the
protocol were monitored. The primary outcome was death or
all-cause hospitalization within 180 days of enrollment.
Results: Of the 5,069 patients screened, 826 underwent ran-
domization to telemonitoring (n = 826) versus usual care (n
= 827). Baseline characteristics were similar between groups.
Mean patient age was 61 years, 86% were New York Heart
Association class II or III, mean creatinine was 1.5 m/dl,
39% were black, 42% were female, and 71% had a left ven-
tricular ejection fraction <40%. Mean household income was
<$10,000 in 28% and 24% did not graduate from high
school. At least one call during the 180-day study was made
by 86% of telemonitoring patients. Patient adherence to the
protocol decreased during the study (90% at 1 week and
55% by 26 weeks). Mortality was 11% in both groups at 180
days. There were no differences between groups in total
readmissions (49% telemonitoring vs. 47% control) or HF-
related readmissions (28% telemonitoring vs. 27% control).
The hazard ratio for the primary endpoint (death/rehospital-
ization) was 1.04; 95% confidence interval, 0.91-1.19). 
Conclusions: Telemonitoring did not improve outcomes in
patients recently hospitalized with HF.
Perspective: Readmission percentages and mortality in this
study were on target with previously published HF studies.
Thus, it appears that this form of telemonitoring does not
impact short-term outcomes in patients with these clinical
characteristics. The decline in adherence to patient-initiated
telemanagement was impressive. Perhaps alternative meth-
ods of telemonitoring that remove the onus from the patient
would be more effective. Overall, there is much heterogene-
ity in study results on HF telemanagement due to the
heterogeneity in the intervention and patient populations
studied. Thus, it continues to be difficult to draw a firm
conclusion regarding the clinical efficacy and cost-effective-
ness of telemanagement.  
Summary written by: Jennifer Ann Cowger, MD
Meta-Analysis: Effect of B-Type Natriuretic Peptide
Testing on Clinical Outcomes in Patients With
Acute Dyspnea in the Emergency Setting
Lam LL, Cameron PA, Schneider HG, Abramson MJ, Muller C, Krum H.
Ann Intern Med 2010;153:728–735.
Study Question: Does B-type natriuretic peptide (BNP) or N-
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ages 18-30 years at baseline.
Results: Over 20 years, maintaining high levels of activity
was associated with smaller gains in body mass index (BMI)
and waist circumference compared with low activity levels
after adjustment for race, baseline BMI, age, education, cig-
arette smoking status, alcohol use, and energy intake. Men
maintaining high activity gained 2.6 fewer kilograms than
those in the lower activity group, and women maintaining
higher activity gained 6.1 fewer kilograms than in the lower
activity group. Men maintaining high activity gained 3.1
fewer centimeters in waist circumference, and women main-
taining higher activity gained 3.8 fewer centimeters. 
Conclusions: Maintaining high activity levels through young
adulthood may lessen weight gain as young adults transition
to middle age, particularly in women.
Perspective: Increasing leisure time and work- or home-
related physical activity is associated with increased fitness
for which there is clear evidence for reduction in overall
mortality, cardiovascular events, coronary risk factors, and
cancer. The observational studies from CARDIA and other
similar cohorts provide governmental agencies, employers,
and others evidence for the value of promoting population
fitness by providing exercise facilities and incentives for chil-
dren through seniors.  
Summary written by: Melvyn Rubenfire, MD
Antihypertensive Drugs and Risk of Cancer:
Network Meta-Analyses and Trial Sequential
Analyses of 324,168 Participants From
Randomized Trials
Bangalore S, Kumar S, Kjeldsen SE, et al.
Lancet Oncol 2010;Nov 30:[Epub ahead of print].
Study Question: Are antihypertensive medications associated
with increased risk of cancer and cancer-related mortality? 
Methods: A literature search using PubMed, Embase, and the
Cochrane Central Register of Controlled Trials was com-
pleted to identify randomized clinical trials of
antihypertensive therapies (angiotensin-receptor blockers
[ARBs], angiotensin-converting enzyme inhibitors [ACEi],
beta-blockers, calcium-channel blockers [CCB], or diuret-
ics) published between 1950 and August 2010. Eligible
trials had to have at least 1-year follow-up, a study popula-
tion of 100 or greater, and reported outcomes, which
included cancer and cancer-related events. The primary out-
comes were occurrence of cancer and cancer-related death.
Results: A total of 70 randomized controlled trials (with
324,168 participants) were included in this meta-analysis.
Mean follow-up was 3.5 years. In the fixed-effect models,
compared with placebo, no differences in risk of cancer
were observed for ARBs (odds ratio [OR], 1.01), ACEi
(OR, 1.00), beta-blockers (OR, 0.97), CCBs (OR, 1.05),
diuretics (OR, 1.00), or other controls (OR, 0.97). An
increased cancer risk was observed for the combination of
ARBs plus ACEi (OR, 1.14). This risk was not observed in
the random-effects model (OR, 1.5). Regarding cancer-
related deaths, no differences were observed for ARBs (OR,
1.00), ACEi (OR, 0.95), beta-blockers (OR, 0.93), CCBs
(OR, 0.96), diuretics (OR, 0.98), other controls (OR, 1.08),
and ACEi plus ARBs (95% CI, 0.90-1.32).
Conclusions: Risk of cancer or cancer-related deaths was not
increased with the use of ARBs, ACEi, beta-blockers, diuret-
ics, and CCBs. However, an increased risk of cancer with the
combination of ACEi and ARBs could not be ruled out. 
Perspective: This meta-analysis provides extensive evidence
that antihypertensive medications in general do not increase
risk for cancer or cancer mortality. It is not clear if the com-
bination of ARBs plus ACEi does in fact increase cancer
risk; however, such a combination is not generally first-line
therapy in the management of hypertension.
Summary written by: Elizabeth A. Jackson, MD
Guidelines for the Primary Prevention of Stroke. A
Guideline for Healthcare Professionals From the
American Heart Association/American Stroke
Association
Goldstein LB, Bushnell CD, Adams RJ, et al.
Stroke 2010;Dec 2:[Epub ahead of print].
Perspective: The following are 10 points to remember about
these guidelines:
1: Approximately 795,000 people in the United States have a
stroke each year, and stroke is the third leading cause of
deaths annually. Although the death rate for stroke fell by
33.5% over the past 10 years, stroke incidence may be
increasing.
2: Stroke prevention efforts can reduce incidence by 50%,
and a healthy lifestyle is associated with an 80% lower risk
of a first stroke. The first goal should be to identify persons
at high risk for stroke including those with nonmodifiable
risk factors for whom more intense treatment of modifiable
risk factors may be indicated.
3: Nonmodifiable risk factors include age (strokes double for
each decade over 55 years); men; Blacks and Hispanic/Latino
Americans; and family history of strokes (e.g., ischemic or
intracranial hemorrhage from aneurysms). Noninvasive screen-
ing of first-degree relatives of persons with subarachnoid
hemorrhage or intracranial aneurysms is not indicated.
4: Modifiable risk factors for stroke include smoking (odds
ratio [OR], 1.9), hypertension (age-related OR, 8.0), diabetes
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(OR, 1.8-6 blood pressure dependent), markedly elevated
cholesterol (OR, 1.5), low high-density lipoprotein cholesterol
(OR, 2.0), atrial fibrillation (age-related OR, 2.6-4.5), asymp-
tomatic carotid stenosis (OR, 2.0), sickle cell (OR, >200),
estrogens (OR, 1.4), physical inactivity (OR, 2.7), and obesity
(OR, 1.4 per 5 kg/m2 increase in body mass index).  
5: Potentially modifiable risk factors include migraine with an
aura, the metabolic syndrome, >4 drinks of alcohol per day,
drug abuse, hyperhomocysteinemia, increased lipoprotein (a),
hypercoagulability, and inflammatory diseases of all types.
6: Hypertension is the most important modifiable risk factor.
There is a lower stroke rate in patients with a blood pressure
target of <120 mm Hg than <140 mm Hg. The blood pres-
sure goal is <140/90 mm Hg, and <130/80 mm Hg in
diabetics and those with chronic kidney disease.
7: Treatment of diabetics for stroke prevention should
include a statin, and an angiotensin-converting enzyme
inhibitor or angiotensin-receptor blocker. The benefit of
aspirin for stroke risk reduction has not been demonstrated
in diabetes, but should be considered in those with high car-
diovascular disease risk.
8: Treatment of dyslipidemias for stroke prevention should
include a statin in persons at high risk for coronary heart dis-
ease and diabetes, possibly in combination with niacin in
patients with a low high-density lipoprotein cholesterol or ele-
vated lipoprotein (a). 
9: Adjusted-dose warfarin (target international normalized
ratio, 2.0-3.0) is recommended for all patients with nonvalvu-
lar atrial fibrillation deemed to be at high risk and those at
moderate risk who are at low risk for warfarin. Antiplatelet
therapy with aspirin is indicated in atrial fibrillation at low
risk or at moderate risk with patient preference or increased
risk for warfarin. Dual antiplatelet therapy is warranted in
high-risk patients unsuitable for warfarin.
10: Carotid artery stenosis is clinically and hemodynamically
significant at a reduction in luminal diameter of >70% on vali-
dated duplex, or >80% on computed tomography angiography
or magnetic resonance angiography. Patients with carotid
stenosis should be treated with lifestyle change and medical
therapy. Population screening for asymptomatic carotid dis-
ease is not recommended. 
Summary written by: Melvyn Rubenfire, MD
Lifetime Fruit and Vegetable Consumption and
Arterial Pulse Wave Velocity in Adulthood: The
Cardiovascular Risk in Young Finns Study
Aatola H, Koivistoinen T, Hutri-Kähönen N, et al.
Circulation 2010;122:2521–2528.
Study Question: Are childhood and young adulthood lifestyle
risk factors determinants of pulse-wave velocity (PWV) in
adults?   
Methods: The study cohort was comprised of 1,622 subjects
of the Cardiovascular Risk in Young Finns Study followed
up for 27 years from baseline (1980; ages 3-18 years) with
lifestyle risk factor data available since childhood. Arterial
PWV was measured in 2007 by whole-body impedance car-
diography.
Results: Mean age at baseline was 10.5 ± 5.0 years, and
54.5% were women. Dietary patterns remained stable from
childhood to adulthood, and especially among older sub-
jects. These patterns were also associated with
cardiovascular risk factors. Vegetable consumption in child-
hood was inversely associated with adulthood PWV (p =
0.02), and this association remained significant (p = 0.004)
when adjusted for traditional risk factors. Vegetable con-
sumption was also an independent predictor of PWV in
adulthood when adjusted for lifestyle or traditional risk fac-
tors (p = 0.002 and p = 0.0007, respectively). Persistently
high consumption of both fruits and vegetables from child-
hood to adulthood was associated with lower PWV
compared with persistently low consumption (p = 0.03 for
both). The number of lifestyle risk factors in childhood was
directly associated with PWV in adulthood (p = 0.001).
This association remained significant when adjusted for the
number of lifestyle risk factors in adulthood (p = 0.003). 
Conclusions: These findings suggest that lifetime lifestyle risk
factors, with low consumption of fruits and vegetables in par-
ticular, are related to arterial stiffness in young adulthood. 
Perspective: Arterial PWV is a marker of central arterial stiff-
ness and is an independent predictor of cardiovascular events
and all-cause mortality. The findings strongly support the rec-
ommendations of a healthy lifestyle in children and young
adults including a diet high in fruits, vegetables, and fiber;
regular exercise; and avoidance of tobacco, each of which can
prevent arterial stiffness associated with increasing age.
Summary written by: Melvyn Rubenfire, MD
Effects of Aerobic and Resistance Training on
Hemoglobin A1c Levels in Patients With Type 2
Diabetes: A Randomized Controlled Trial
Church TS, Blair SN, Cocreham S, et al.
JAMA 2010;304:2253–2262.
Study Question: What are the benefits of aerobic training
alone, resistance training alone, and the combination of
both on hemoglobin A1c (HbA1c) in individuals with type
2 diabetes? 
Methods: A randomized controlled trial was conducted in 262
sedentary men and women with type 2 diabetes and HbA1c
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levels of 6.5% or higher. Participants were randomized to one
of the three exercise protocols for 9 months between April
2007 and August 2009. Exercise intensity was 50-80% of
maximum oxygen consumption with an aerobic dose of 12
kcal/kg/wk for the aerobic group and 10 kcal/kg/wk for the
combination exercise group.
Results: A total of 63% were women and 47.3% were non-
white. Mean age was 55.8 years, mean duration of diabetes
was 7.1 years, mean body mass index was 34.9 kg/m2, and
baseline HbA1c level was 7.7%; 97% were on one or more
hypoglycemic agents, 18% of which included insulin.
Compared with the control group, the absolute mean change
in HbA1c in the combination training exercise group was
−0.34%. The mean changes in HbA1c were not statistically
significant in either the resistance training or aerobic training
groups. Only the combination exercise group improved maxi-
mum oxygen consumption (mean, 1.0 ml/kg/min) compared
with controls. All exercise groups reduced waist circumference
from −1.9 to −2.8 cm compared with controls. The resistance
training group lost a mean of −1.4 kg fat mass and combina-
tion training group lost a mean of −1.7 compared with
controls. 
Conclusions: Among patients with type 2 diabetes mellitus, a
combination of aerobic and resistance training compared with
the nonexercise control group improved HbA1c levels. This
was not achieved by aerobic or resistance training alone. 
Perspective: This well-designed study strongly supports the
2008 Physical Activity Guidelines recommendation that opti-
mal physical activity programs consist of regular physical
activity combined with resistance training. To achieve the goal
kcal/kg/wk, participants exercised about 150 minutes per
week. Considering the added benefit on other cardiovascular
risk factors, quality of life, and other clinical endpoints, con-
sideration should be given to a cost-effective strategy for
providing supervised exercise for diabetics.
Summary written by: Melvyn Rubenfire, MD
Intensive Lowering of LDL Cholesterol With 80 mg
Versus 20 mg Simvastatin Daily in 12,064
Survivors of Myocardial Infarction: A Double-Blind
Randomised Trial
Study of the Effectiveness of Additional Reductions in Cholesterol
and Homocysteine (SEARCH) Collaborative Group.
Lancet 2010;376:1658–1669.
Study Question: Does more intensive statin therapy improve
total and cardiovascular outcome following a myocardial
infarction (MI), and if so at what risk?  
Methods: SEARCH is a double-blind randomized trial in
12,064 men and women ages 18-80 years with a history of
MI. Participants were either currently on or had clear indi-
cation for statin therapy, and had a total cholesterol concen-
tration of at least 135 mg/dl if already on a statin or 175
mg/dl if not. Randomization to either 80 mg or 20 mg sim-
vastatin daily was done centrally using a minimization
algorithm. An additional placebo-controlled trial tested the
efficacy of vitamin B12 + folic acid for lowering homocys-
teine. Participants were assessed at 2, 4, 8, and 12 months
after randomization and then every 6 months until final fol-
low-up. The primary endpoint was major vascular events,
defined as coronary death, MI, stroke, or arterial revascular-
ization. 
Results: A total of 6,031 participants were allocated 80 mg
simvastatin daily, and 6,033 were allocated 20 mg simva-
statin daily; 84% were men and average age was 64.2 years.
Nearly 75% were taking a statin prior to entry. During a
mean follow-up of 6.7 years, allocation to 80 mg simvas-
tatin produced an average 1.5 mg/dl greater reduction in
low-density lipoprotein cholesterol (LDL-C) compared
with 20 mg. Major vascular events occurred in 1,477
(24.5%) participants allocated 80 mg simvastatin versus
1,553 (25.7%) allocated 20 mg, corresponding to a 6% pro-
portional reduction. There were no apparent differences in
numbers of hemorrhagic strokes or deaths attributed to vas-
cular or nonvascular causes. An insignificantly lower
number of cancers occurred on 80 mg simvastatin.
Compared with two (0.03%) cases of myopathy in patients
taking 20 mg simvastatin daily, there were 53 (0.9%) cases
in the 80 mg group, of whom 2/1,000 had a creatine kinase
40x ULN. 
Conclusions: The 6% reduction in major vascular events with a
further 1.5 mg/dl reduction in LDL-C in the SEARCH trial
is consistent with previous trials. Myopathy was increased
with 80 mg simvastatin daily, but intensive lowering of LDL-
C can be achieved safely with other regimens. 
Perspective: The large SEARCH trial offers further confirma-
tion that higher statin doses and lower levels of LDL-C
achieved improve outcome. The disappointingly modest fur-
ther reduction in cardiovascular events from 80 mg versus 40
mg of simvastatin has several potential explanations. Most
importantly nearly 75% were on statins, which biases against
being able to demonstrate efficacy, and the 80 mg dose of
simvastatin provided only a 6% further reduction in LDL-C
than the 20 mg dose. I agree with the authors, who con-
cluded lower is better and that better alternatives for efficacy
and safety to 80 mg simvastatin include atorvastatin 80 mg,
rosuvastatin 20-40 mg, or simvastatin + other cholesterol-
lowering agents that do no increase the risk of myopathy.
Summary written by: Melvyn Rubenfire, MD
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